Sialexin Mechanism of Action

Pharmacology: Pharmacodynamics: SIALEXIN is a first generation of cephalosporins antibiotic SIALEXIN inhibits cell wall synthesis by binding the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacteria cell walls.
In vitro Cephalexin is susceptible to gram positive and gram negative bacteria.
Gram-positive aerobic bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes (Group A β-hemolytic Streptococci), Streptococcus agalactiae (Group A β-Streptococci) and Streptococcus pneumoniae.
Gram negative aerobic bacteria: Escherichia coli, Haemophilus influenzae, Neisseria catarrhalis, Klebsiella pneumoniae, Proteus mirabilis and Shigella sp.
Pharmacokinetics: Cephalexin is rapidly and completely absorbed from GI tract. Absorption of Cephalexin is delayed in young children and may be decreased up to 50% in neonate. Peak serum concentrations of the drug have been reported to occur within 3 hours in infants younger than 6 months of age, within 2 hours in children 9-12 months of age, and within 1 hour in older children and adults. When Cephalexin is administered with food, peak serum concentration is minimally decreased and time to reach peak serum concentration is delayed.
However extent of absorption is unchanged. Cephalexin is widely distributed into body tissue and fluids i.e. liver, kidney and bone but it is poorly distributed to synovial fluids and cerebrospinal fluid. The drug can distribute across placenta, and enters breast milk. Protein binding of Cephalexin is 6%-15%, Cephalexin is mainly excreted in urine as uncharged. The serum half-life of Cephalexin is 0.5-1.2 hours in adults with normal renal function and longer in patient with renal impairment.